Obesity and leukemia: Biological mechanisms, perspectives, and challenges

1.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2. International Agency for Research on Cancer; 2017.

2.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

3.

Lin L, Yan L, Liu Y, Yuan F, Li H, Ni J. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 2019;12:96. https://doi.org/10.1186/s13045-019-0783-9.CrossRefPubMedPubMedCentral

4.

Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. 2020:10. https://doi.org/10.1101/cshperspect.a034819.

5.

Du M, Chen W, Liu K, Wang L, Hu Y, Mao Y, et al. The Global burden of leukemia and its attributable factors in 204 countries and territories: Findings from the global burden of disease 2019 study and projections to 2030. J Oncol. 2022;2022:1612702. https://doi.org/10.1155/2022/1612702.CrossRefPubMedPubMedCentral

6.

Dalamaga M, Petridou E, Cook FE, Trichopoulos D. Risk factors for myelodysplastic syndromes: A case-control study in Greece. Cancer Causes Control. 2002;13:603–8. https://doi.org/10.1023/a:1019573319803.CrossRefPubMed

7.

Hao T, Li-Talley M, Buck A, Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep. 2019;9:12070. https://doi.org/10.1038/s41598-019-48445-1.CrossRefPubMedPubMedCentralADS

8.

Dalamaga M, Lekka A, Karmaniolas K, Stathopoulou E, Dionyssiou-Asteriou A. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome? Cancer Causes Control. 2008;19:371–8. https://doi.org/10.1007/s10552-007-9096-3.CrossRefPubMed

9.

Dalamaga M, Crotty BH, Fargnoli J, Papadavid E, Lekka A, Triantafilli M, et al. B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: A case-control study in Greece. Cancer Causes Control. 2010;21:1451–9. https://doi.org/10.1007/s10552-010-9573-y.CrossRefPubMedPubMedCentral

10.

Petridou E, Dalamaga M, Mentis A, Skalkidou A, Moustaki M, Karpathios T, et al. Evidence on the infectious etiology of childhood leukemia: The role of low herd immunity (Greece). Cancer Causes Control. 2001;12:645–52. https://doi.org/10.1023/a:1011255825887.CrossRefPubMed

11.

Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist. 2010;15:1083–101. https://doi.org/10.1634/theoncologist.2010-0206.CrossRefPubMedPubMedCentral

12.

Hroussalas G, Kassi E, Dalamaga M, Delimaris I, Zachari A, Dionyssiou-Asteriou A. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas. 2008;59:339–49. https://doi.org/10.1016/j.maturitas.2008.03.012.CrossRefPubMed

13.

Kassi E, Dalamaga M, Faviou E, Hroussalas G, Kazanis K, Nounopoulos C, et al. Circulating oxidized LDL levels, current smoking and obesity in postmenopausal women. Atherosclerosis. 2009;205:279–83. https://doi.org/10.1016/j.atherosclerosis.2008.11.006.CrossRefPubMed

14.

Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: Current evidence and treatment considerations. Curr Obes Rep. 2020;9:165–78. https://doi.org/10.1007/s13679-020-00380-3.CrossRefPubMed

15.

Koliaki C, Liatis S, Dalamaga M, Kokkinos A. The implication of gut hormones in the regulation of energy homeostasis and their role in the pathophysiology of obesity. Curr Obes Rep. 2020;9:255–71. https://doi.org/10.1007/s13679-020-00396-9.CrossRefPubMed

16.

Stratigou T, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Christodoulatos GS, et al. Hyperirisinemia is independently associated with subclinical hypothyroidism: Correlations with cardiometabolic biomarkers and risk factors. Endocrine. 2018;61:83–93. https://doi.org/10.1007/s12020-018-1550-3.CrossRefPubMed

17.

Fogarasi A, Gonzalez K, Dalamaga M, Magkos F. The impact of the rate of weight loss on body composition and metabolism. Curr Obes Rep. 2022;11:33–44. https://doi.org/10.1007/s13679-022-00470-4.CrossRefPubMed

18.

WHO. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed on March 25, 2023.

19.

Liu J, Tsilingiris D, Dalamaga M. The non-linear relationship between muscle mass and BMI calls into question the use of BMI as a major criterion for eligibility for bariatric surgery. Metabol Open. 2022;13:100164. https://doi.org/10.1016/j.metop.2022.100164.CrossRefPubMedPubMedCentral

20.

Simati S, Kokkinos A, Dalamaga M, Argyrakopoulou G. Obesity paradox: Fact or fiction? Curr Obes Rep. 2023;12:75–85. https://doi.org/10.1007/s13679-023-00497-1.CrossRefPubMed

21.

Afshin A, Reitsma MB, Murray CJL. Health effects of overweight and obesity in 195 countries. N Engl J Med. 2017;377:1496–7. https://doi.org/10.1056/NEJMc1710026.CrossRefPubMed

22.

Karampela I, Vallianou N, Magkos F, Apovian CM, Dalamaga M. Obesity, hypovitaminosis D, and COVID-19: The Bermuda triangle in public health. Curr Obes Rep. 2022;11:116–25. https://doi.org/10.1007/s13679-022-00471-3.CrossRefPubMedPubMedCentral

23.

Cardel MI, Atkinson MA, Taveras EM, Holm JC, Kelly AS. Obesity treatment among adolescents: A review of current evidence and future directions. JAMA Pediatr. 2020;174:609–17. https://doi.org/10.1001/jamapediatrics.2020.0085.CrossRefPubMedPubMedCentral

24.

Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Semin Cancer Biol. 2021;73:356–76. https://doi.org/10.1016/j.semcancer.2021.05.008.CrossRefPubMed

25.

Tsilingiris D, Liatis S, Dalamaga M, Kokkinos A. The fight against obesity escalates: New Drugs on the horizon and metabolic implications. Curr Obes Rep. 2020;9:136–49. https://doi.org/10.1007/s13679-020-00378-x.CrossRefPubMed

26.

Tsigalou C, Vallianou N, Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? Curr Obes Rep. 2020;9:245–54. https://doi.org/10.1007/s13679-020-00397-8.CrossRefPubMed

27.

Dalamaga M, Papadavid E, Basios G, Vaggopoulos V, Rigopoulos D, Kassanos D, et al. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: A prospective controlled study. J Am Acad Dermatol. 2013;69:922–30. https://doi.org/10.1016/j.jaad.2013.09.014.CrossRefPubMed

28.

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8. https://doi.org/10.1056/NEJMsr1606602.CrossRefPubMedPubMedCentral

29.

Larsson SC, Spyrou N, Mantzoros CS. Body fatness associations with cancer: Evidence from recent epidemiological studies and future directions. Metabolism. 2022;137:155326. https://doi.org/10.1016/j.metabol.2022.155326.CrossRefPubMed

30.

Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: A meta-analysis of prospective cohort studies. Leuk Res. 2012;36:868–75. https://doi.org/10.1016/j.leukres.2011.12.020.CrossRefPubMed

31.

Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: A meta-analysis of cohort studies. Int J Cancer. 2008;122:1418–21. https://doi.org/10.1002/ijc.23176.CrossRefPubMed

32.

Lichtman MA. Obesity and the risk of chronic myelogenous leukemia: Is this another example of the neoplastic effects of increased body fat? Leukemia. 2012;26:183–4. https://doi.org/10.1038/leu.2011.190.CrossRefPubMed

33.

Teras LR, Patel AV, Carter BD, Rees-Punia E, McCullough ML, Gapstur SM. Anthropometric factors and risk of myeloid leukaemias and myelodysplastic syndromes: A prospective study and meta-analysis. Br J Haematol. 2019;186:243–54. https://doi.org/10.1111/bjh.15904.CrossRefPubMed

34.

Poynter JN, Richardson M, Blair CK, Roesler MA, Hirsch BA, Nguyen P, et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 2016;40:134–40. https://doi.org/10.1016/j.canep.2015.12.005.CrossRefPubMed

35.

Dalamaga M, Karmaniolas K, Lekka A, Antonakos G, Thrasyvoulides A, Papadavid E, et al. Platelet markers correlate with glycemic indices in diabetic, but not diabetic-myelodysplastic patients with normal platelet count. Dis Markers. 2010;29:55–61. https://doi.org/10.3233/dma-2010-0726.CrossRefPubMedPubMedCentral

36.

Bhaskaran K, Douglas I, Forbes H, dos Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–65. https://doi.org/10.1016/s0140-6736(14)60892-8.CrossRefPubMedPubMedCentral

37.

Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: Estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72. https://doi.org/10.1186/s13045-020-00908-z.CrossRefPubMedPubMedCentral

38.

Huang J, Chan SC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. Disease Burden, risk factors, and trends of leukaemia: A global analysis. Front Oncol. 2022;12:904292. https://doi.org/10.3389/fonc.2022.904292.CrossRefPubMedPubMedCentral

39.

Ahmed M, Mäkinen VP, Lumsden A, Boyle T, Mulugeta A, Lee SH, et al. Metabolic profile predicts incident cancer: A large-scale population study in the UK Biobank. Metabolism. 2023;138:155342. https://doi.org/10.1016/j.metabol.2022.155342.CrossRefPubMed

40.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38. https://doi.org/10.1056/NEJMoa021423.CrossRefPubMed

41.

Amankwah EK, Saenz AM, Hale GA, Brown PA. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: A systematic review and meta-analysis. Leuk Lymphoma. 2016;57:1140–8. https://doi.org/10.3109/10428194.2015.1076815.CrossRefPubMed

42.

Jeddi R, Ghédira H, Mnif S, Gouider E, Fenaux P, Meddeb B. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2010;34:545–7. https://doi.org/10.1016/j.leukres.2009.09.017.CrossRefPubMed

43.

Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009;18:1501–6. https://doi.org/10.1158/1055-9965.Epi-09-0028.CrossRefPubMedPubMedCentral

44.

Wong O, Harris F, Yiying W, Hua F. A hospital-based case-control study of acute myeloid leukemia in Shanghai: Analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol. 2009;55:340–52. https://doi.org/10.1016/j.yrtph.2009.08.007.CrossRefPubMed

45.

Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2348–54. https://doi.org/10.1158/1055-9965.Epi-06-0007.CrossRefPubMed

46.

Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16:489–500. https://doi.org/10.1007/s10552-004-7115-1.CrossRefPubMed

47.

Ross JA, Parker E, Blair CK, Cerhan JR, Folsom AR. Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev. 2004;13:1810–3.CrossRefPubMed

48.

Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997;11:1661–4. https://doi.org/10.1038/sj.leu.2400783.CrossRefPubMed

49.

Ma X, Lim U, Park Y, Mayne ST, Wang R, Hartge P, et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009;169:1492–9. https://doi.org/10.1093/aje/kwp074.CrossRefPubMedPubMedCentral

50.

Reagan JL, Ingham RR II, Dalia S, Furman M, Merhi B, Nemr S, et al. Association between obesity/overweight and leukemia: A meta-analysis of prospective cohort studies. Blood. 2011;118:3588. https://doi.org/10.1182/blood.V118.21.3588.3588.CrossRef

51.

Mazzarella L, Botteri E, Matthews A, Gatti E, Di Salvatore D, Bagnardi V, et al. Obesity is a risk factor for acute promyelocytic leukemia: Evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. Haematologica. 2020;105:1559–66. https://doi.org/10.3324/haematol.2019.223925.CrossRefPubMedPubMedCentral

52.

Milne E, Royle JA, de Klerk NH, Blair E, Bailey H, Cole C, et al. Fetal growth and risk of childhood acute lymphoblastic leukemia: Results from an Australian case-control study. Am J Epidemiol. 2009;170:221–8. https://doi.org/10.1093/aje/kwp117.CrossRefPubMed

53.

Caughey RW, Michels KB. Birth weight and childhood leukemia: A meta-analysis and review of the current evidence. Int J Cancer. 2009;124:2658–70. https://doi.org/10.1002/ijc.24225.CrossRefPubMed

54.

Huang T, Ducore JM. Children and adolescents with ALL are taller than expected at diagnosis. J Pediatr Hematol Oncol. 2014;36:16–21. https://doi.org/10.1097/MPH.0b013e31829bcb10.CrossRefPubMed

55.

Schraw JM, Henson AT, Scheurer ME, Forman MR. The associations of height-for-age, weight-for-age, and weight-for-height with pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39:376–81. https://doi.org/10.1097/mph.0000000000000874.CrossRefPubMed

56.

Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, et al. Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer. 2010;54:242–9. https://doi.org/10.1002/pbc.22308.CrossRefPubMedPubMedCentral

57.

Stacy SL, Buchanich JM, Ma ZQ, Mair C, Robertson L, Sharma RK, et al. Maternal obesity, birth size, and risk of childhood cancer development. Am J Epidemiol. 2019;188:1503–11. https://doi.org/10.1093/aje/kwz118.CrossRefPubMedPubMedCentral

58.

•• Jiménez-Hernández E, Fajardo-Gutiérrez A, Núñez-Enriquez JC, Martín-Trejo JA, Espinoza-Hernández LE, Flores-Lujano J, et al. A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL). Cancer Med. 2018;7:1528–36. https://doi.org/10.1002/cam4.1414. This is an interesting original research study among Mexican children that demonstrated a relationship between greater birth weight and increased risk of acute leukemia.CrossRefPubMedPubMedCentral

59.

Tran LT, Lai HTM, Koriyama C, Uwatoko F, Akiba S. The association between high birth weight and the risks of childhood CNS tumors and leukemia: An analysis of a US case-control study in an epidemiological database. BMC Cancer. 2017;17:687. https://doi.org/10.1186/s12885-017-3681-y.CrossRefPubMedPubMedCentral

60.

Hjalgrim LL, Westergaard T, Rostgaard K, Schmiegelow K, Melbye M, Hjalgrim H, et al. Birth weight as a risk factor for childhood leukemia: A meta-analysis of 18 epidemiologic studies. Am J Epidemiol. 2003;158:724–35. https://doi.org/10.1093/aje/kwg210.CrossRefPubMed

61.

Marley AR, Ryder JR, Turcotte LM, Spector LG. Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms. Leuk Res. 2022;121:106924. https://doi.org/10.1016/j.leukres.2022.106924.CrossRefPubMed

62.

Marley AR, Domingues A, Ghosh T, Turcotte LM, Spector LG. Maternal body mass index, diabetes, and gestational weight gain and risk for pediatric cancer in offspring: A systematic review and meta-analysis. JNCI Cancer Spectr. 2022:6. https://doi.org/10.1093/jncics/pkac020.

63.

Dalamaga M, Stratigou T, Tsilingiris D. Body composition and fat depot assessment: Going supersonic to improve cardiometabolic outcomes. Pol. Arch Intern Med. 2022:132. https://doi.org/10.20452/pamw.16362.

64.

Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35. https://doi.org/10.1016/j.metabol.2018.11.001.CrossRefPubMed

65.

Foster KL, Kern KD, Chambers TM, Lupo PJ, Kamdar KY, Scheurer ME, et al. Weight trends in a multiethnic cohort of pediatric acute lymphoblastic leukemia survivors: A longitudinal analysis. PLoS One. 2019;14:e0217932. https://doi.org/10.1371/journal.pone.0217932.CrossRefPubMedPubMedCentral

66.

Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008;26:4639–45. https://doi.org/10.1200/jco.2008.16.3527.CrossRefPubMedPubMedCentral

67.

Zhang FF, Kelly MJ, Saltzman E, Must A, Roberts SB, Parsons SK. Obesity in pediatric ALL survivors: A meta-analysis. Pediatrics. 2014;133:e704–15. https://doi.org/10.1542/peds.2013-3332.CrossRefPubMedPubMedCentral

68.

• Richard MA, Brown AL, Belmont JW, Scheurer ME, Arroyo VM, Foster KL, et al. Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer. 2021;127:310–8. https://doi.org/10.1002/cncr.33258. In this multicentric study, adult survivors of childhood ALL have genetic heritability for BMI similar to that observed in the general population, providing evidence that treatment with cranial radiation therapy can modify the effect of genetic variants on adult BMI in childhood ALL survivors.CrossRefPubMed

69.

Green DM, Cox CL, Zhu L, Krull KR, Srivastava DK, Stovall M, et al. Risk factors for obesity in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2012;30:246–55. https://doi.org/10.1200/jco.2010.34.4267.CrossRefPubMed

70.

Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature. 2017;541:81–6. https://doi.org/10.1038/nature20784.CrossRefPubMedADS

71.

•• Lupo PJ, Brown AL, Arroyo VM, Kamdar KY, Belmont JW, Scheurer ME, et al. DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Genes Chromosomes Cancer. 2019;58:52–9. https://doi.org/10.1002/gcc.22701. A very interesting original study showing that BMI-DNA methylation loci differ between ALL survivors, who received only chemotherapy when compared to those that received cranial radiotherapy as well.CrossRefPubMed

72.

Pramanik R, Sheng X, Ichihara B, Heisterkamp N, Mittelman SD. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. Leuk Res. 2013;37:503–9. https://doi.org/10.1016/j.leukres.2012.12.013.CrossRefPubMedPubMedCentral

73.

Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69:7867–74. https://doi.org/10.1158/0008-5472.Can-09-0800.CrossRefPubMedPubMedCentral

74.

Dushnicky MJ, Nazarali S, Mir A, Portwine C, Samaan MC. Is there a causal relationship between childhood obesity and acute lymphoblastic leukemia? A review. Cancers (Basel). 2020:12. https://doi.org/10.3390/cancers12113082.

75.

Núñez-Enríquez JC, Gil-Hernández AE, Jiménez-Hernández E, Fajardo-Gutiérrez A, Medina-Sansón A, Flores-Lujano J, et al. Overweight and obesity as predictors of early mortality in Mexican children with acute lymphoblastic leukemia: A multicenter cohort study. BMC Cancer. 2019;19:708. https://doi.org/10.1186/s12885-019-5878-8.CrossRefPubMedPubMedCentral

76.

Ehsanipour EA, Sheng X, Behan JW, Wang X, Butturini A, Avramis VI, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 2013;73:2998–3006. https://doi.org/10.1158/0008-5472.Can-12-4402.CrossRefPubMedPubMedCentral

77.

Sheng X, Tucci J, Parmentier JH, Ji L, Behan JW, Heisterkamp N, et al. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. Oncotarget. 2016;7:73147–59. https://doi.org/10.18632/oncotarget.12246.CrossRefPubMedPubMedCentral

78.

Lee M, Hamilton JAG, Talekar GR, Ross AJ, Michael L, Rupji M, et al. Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. Nat Commun. 2022;13:1157. https://doi.org/10.1038/s41467-022-28839-y.CrossRefPubMedPubMedCentralADS

79.

Sheng X, Mittelman SD. The role of adipose tissue and obesity in causing treatment resistance of acute lymphoblastic leukemia. Front Pediatr. 2014;2:53. https://doi.org/10.3389/fped.2014.00053.CrossRefPubMedPubMedCentral

80.

Sheng X, Parmentier JH, Tucci J, Pei H, Cortez-Toledo O, Dieli-Conwright CM, et al. Adipocytes sequester and metabolize the chemotherapeutic daunorubicin. Mol Cancer Res. 2017;15:1704–13. https://doi.org/10.1158/1541-7786.Mcr-17-0338.CrossRefPubMedPubMedCentral

81.

• Shimony S, Flamand Y, Valtis YK, Place AE, Silverman LB, Vrooman LM, et al. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL Trials. Blood Adv. 2023;7:5234–45. https://doi.org/10.1182/bloodadvances.2023009976. Amid adolescent and young adults with acute lymphoblastic leukemia treated on DFCI Consortium ALL regimens, elevated BMI was associated with increased toxicity and decreased overall survival.CrossRefPubMedPubMedCentral

82.

Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, et al. The impact of obesity on the outcomes of adult patients with acute lymphoblastic leukemia - a single center retrospective study. Blood Lymphat Cancer. 2021;11:1–9. https://doi.org/10.2147/blctt.S269748.CrossRefPubMedPubMedCentral

83.

Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012;97:1401–4. https://doi.org/10.3324/haematol.2011.056390.CrossRefPubMedPubMedCentral

84.

Dhakal P, Lyden E, Lee A, Michalski J, Al-Kadhimi ZS, Maness LJ, et al. Effects of obesity on overall survival of adults with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:e131–e6. https://doi.org/10.1016/j.clml.2019.11.001.CrossRefPubMed

85.

Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis. Sci Rep. 2017;7:17998. https://doi.org/10.1038/s41598-017-18278-x.CrossRefPubMedPubMedCentralADS

86.

Baillargeon J, Langevin AM, Lewis M, Estrada J, Mullins J, Pitney A, et al. Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2006;28:575–8. https://doi.org/10.1097/01.mph.0000212985.33941.d8.CrossRefPubMed

87.

Ethier MC, Alexander S, Abla O, Green G, Lam R, Sung L. Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53:1677–81. https://doi.org/10.3109/10428194.2012.664843.CrossRefPubMed

88.

Aldhafiri FK, McColl JH, Reilly JJ. Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2014;36:234–6. https://doi.org/10.1097/mph.0000000000000056.CrossRefPubMed

89.

Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: A meta-analysis. Am J Clin Nutr. 2016;103:808–17. https://doi.org/10.3945/ajcn.115.124586.CrossRefPubMedPubMedCentral

90.

Saenz AM, Stapleton S, Hernandez RG, Hale GA, Goldenberg NA, Schwartz S, et al. Body mass index at pediatric leukemia diagnosis and the risks of relapse and mortality: Findings from a single institution and meta-analysis. J Obes. 2018;2018:7048078. https://doi.org/10.1155/2018/7048078.CrossRefPubMedPubMedCentral

91.

Gelelete CB, Pereira SH, Azevedo AM, Thiago LS, Mundim M, Land MG, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity (Silver Spring). 2011;19:1908–11. https://doi.org/10.1038/oby.2011.195.CrossRefPubMed

92.

Núñez-Enríquez JC, Bárcenas-López DA, Hidalgo-Miranda A, Jiménez-Hernández E, Bekker-Méndez VC, Flores-Lujano J, et al. Gene expression profiling of acute lymphoblastic leukemia in children with very early relapse. Arch Med Res. 2016;47:644–55. https://doi.org/10.1016/j.arcmed.2016.12.005.CrossRefPubMed

93.

Gaggini M, Carli F, Gastaldelli A. The color of fat and its central role in the development and progression of metabolic diseases. Horm Mol Biol. Clin Investig. 2017:31. https://doi.org/10.1515/hmbci-2017-0060.

94.

Cinti S. Pink Adipocytes. Trends Endocrinol Metab. 2018;29:651–66. https://doi.org/10.1016/j.tem.2018.05.007.CrossRefPubMed

95.

Karampela I, Christodoulatos GS, Dalamaga M. The role of adipose tissue and adipokines in sepsis: Inflammatory and metabolic considerations, and the obesity paradox. Curr Obes Rep. 2019;8:434–57. https://doi.org/10.1007/s13679-019-00360-2.CrossRefPubMed

96.

Li Y, Cao S, Gaculenko A, Zhan Y, Bozec A, Chen X. Distinct metabolism of bone marrow adipocytes and their role in bone metastasis. Front Endocrinol (Lausanne). 2022;13:902033. https://doi.org/10.3389/fendo.2022.902033.CrossRefPubMedPubMedCentral

97.

Piotrowska K, Tarnowski M. Bone marrow adipocytes-role in physiology and various nutritional conditions in human and animal models. Nutrients. 2021:13. https://doi.org/10.3390/nu13051412.

98.

Martinez LM, Guzman ML. Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches. Br J Pharmacol. 2023; https://doi.org/10.1111/bph.16162.

99.

Pottosin I, Olivas-Aguirre M, Dobrovinskaya O. In vitro simulation of the acute lymphoblastic leukemia niche: A critical view on the optimal approximation for drug testing. J Leukoc Biol. 2023;114:21–41. https://doi.org/10.1093/jleuko/qiad039.CrossRefPubMed

100.

Karamanakos G, Kokkinos A, Dalamaga M, Liatis S. Highlighting the role of obesity and insulin resistance in type 1 diabetes and its associated cardiometabolic complications. Curr Obes Rep. 2022;11:180–202. https://doi.org/10.1007/s13679-022-00477-x.CrossRefPubMed

101.

Tsilingiris D, Dalamaga M, Liu J. SARS-CoV-2 adipose tissue infection and hyperglycemia: A further step towards the understanding of severe COVID-19. Metabol Open. 2022;13:100163. https://doi.org/10.1016/j.metop.2022.100163.CrossRefPubMedPubMedCentral

102.

Tsilingiris D, Tzeravini E, Koliaki C, Dalamaga M, Kokkinos A. The role of mitochondrial adaptation and metabolic flexibility in the pathophysiology of obesity and insulin resistance: An updated overview. Curr Obes Rep. 2021;10:191–213. https://doi.org/10.1007/s13679-021-00434-0.CrossRefPubMed

103.

Dalamaga M, Karmaniolas K, Chamberland J, Nikolaidou A, Lekka A, Dionyssiou-Asteriou A, et al. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. Metabolism. 2013;62:1830–9. https://doi.org/10.1016/j.metabol.2013.09.007.CrossRefPubMed

104.

Leitner BP, Siebel S, Akingbesote ND, Zhang X, Perry RJ. Insulin and cancer: A tangled web. Biochem J. 2022;479:583–607. https://doi.org/10.1042/bcj20210134.CrossRefPubMed

105.

Søndergaard CS, Esquivel PN, Dalamaga M, Magkos F. Use of antihyperglycemic drugs and risk of cancer in patients with diabetes. Curr Oncol Rep. 2023;25:29–40. https://doi.org/10.1007/s11912-022-01344-7.CrossRefPubMed

106.

Stratigou T, Muscogiuri G, Kotopouli M, Antonakos G, Christodoulatos GS, Karampela I, et al. Lower circulating omentin-1 is independently linked to subclinical hypothyroidism reflecting cardiometabolic risk: An observational case-control and interventional, longitudinal study. Panminerva Med. 2022;64:452–64. https://doi.org/10.23736/s0031-0808.22.04701-2.CrossRefPubMed

107.

Christodoulatos GS, Antonakos G, Karampela I, Psallida S, Stratigou T, Vallianou N, et al. Circulating Omentin-1 as a biomarker at the intersection of postmenopausal breast cancer occurrence and cardiometabolic risk: An observational cross-sectional study. Biomolecules. 2021:11. https://doi.org/10.3390/biom11111609.

108.

Spyrou N, Avgerinos KI, Mantzoros CS, Dalamaga M. Classic and novel adipocytokines at the intersection of obesity and cancer: Diagnostic and therapeutic strategies. Curr Obes Rep. 2018;7:260–75. https://doi.org/10.1007/s13679-018-0318-7.CrossRefPubMed

109.

Kasuga M, Kahn CR, Hedo JA, Van Obberghen E, Yamada KM. Insulin-induced receptor loss in cultured human lymphocytes is due to accelerated receptor degradation. Proc Natl Acad Sci U S A. 1981;78:6917–21. https://doi.org/10.1073/pnas.78.11.6917.CrossRefPubMedPubMedCentralADS

110.

Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:2679–92. https://doi.org/10.1158/1078-0432.Ccr-10-2058.CrossRefPubMedPubMedCentral

111.

Chen PM, Kwan SH, Hwang TS, Chiang BN, Chou CK. Insulin receptors on leukemia and lymphoma cells. Blood. 1983;62:251–5.CrossRefPubMed

112.

Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208:1809–22. https://doi.org/10.1084/jem.20110121.CrossRefPubMedPubMedCentral

113.

Yaktapour N, Übelhart R, Schüler J, Aumann K, Dierks C, Burger M, et al. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 2013;122:1621–33. https://doi.org/10.1182/blood-2013-02-484386.CrossRefPubMed

114.

Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: Therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 2010;95:415–23. https://doi.org/10.3324/haematol.2009.010785.CrossRefPubMed

115.

Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol. 2022;12:819128. https://doi.org/10.3389/fonc.2022.819128.CrossRefPubMedPubMedCentral

116.

Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009;7:14. https://doi.org/10.1186/1478-811x-7-14.CrossRefPubMedPubMedCentral

117.

Machado-Neto JA, Fenerich BA, Rodrigues Alves APN, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, et al. Insulin substrate receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics (Sao Paulo). 2018;73:e566s. https://doi.org/10.6061/clinics/2018/e566s.CrossRefPubMedPubMedCentral

118.

Traina F, Carvalheira JB, Saad MJ, Costa FF, Saad ST. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Lett. 2003;535:17–22. https://doi.org/10.1016/s0014-5793(02)03845-0.CrossRefPubMed

119.

Yin T, Keller SR, Quelle FW, Witthuhn BA, Tsang ML, Lienhard GE, et al. Interleukin-9 induces tyrosine phosphorylation of insulin receptor substrate-1 via JAK tyrosine kinases. J Biol Chem. 1995;270:20497–502. https://doi.org/10.1074/jbc.270.35.20497.CrossRefPubMed

120.

Savage SL, Eide CA, Concannon KF, Bottomly D, Wilmot B, McWeeney SK, et al. Activating mutations of insulin receptor substrate 2 (IRS2) in patients with tyrosine kinase inhibitor-refractory chronic myeloid leukemia. Blood. 2015;126:2461. https://doi.org/10.1182/blood.V126.23.2461.2461.CrossRef

121.

Zhao H, Liu F, Jia R, Chang H, Li H, Miao M, et al. MiR-570 inhibits cell proliferation and glucose metabolism by targeting IRS1 and IRS2 in human chronic myelogenous leukemia. Iran J Basic Med Sci. 2017;20:481–8. https://doi.org/10.22038/ijbms.2017.8671.CrossRefPubMedPubMedCentral

122.

de Melo CP, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget. 2016;7:6948–59. https://doi.org/10.18632/oncotarget.6851.CrossRef

123.

Chang YC, Lin HC, Chiang YH, Chen CG, Huang L, Wang WT, et al. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017;34:83. https://doi.org/10.1007/s12032-017-0944-z.CrossRefPubMed

124.

Fernandes JC, Rodrigues Alves APN, Machado-Neto JA, Scopim-Ribeiro R, Fenerich BA, da Silva FB, et al. IRS1/β-catenin axis is activated and induces MYC expression in acute lymphoblastic leukemia cells. J Cell Biochem. 2017;118:1774–81. https://doi.org/10.1002/jcb.25845.CrossRefPubMed

125.

Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007;25:1341–9. https://doi.org/10.1200/jco.2006.09.3534.CrossRefPubMed

126.

Ye W, Jiang Z, Lu X, Ren X, Deng M, Lin S, et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget. 2017;8:87002–15. https://doi.org/10.18632/oncotarget.10881.CrossRefPubMed

127.

Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999;19:7203–15. https://doi.org/10.1128/mcb.19.10.7203.CrossRefPubMedPubMedCentral

128.

Guo S. Insulin signaling, resistance, and the metabolic syndrome: Insights from mouse models into disease mechanisms. J Endocrinol. 2014;220:T1–t23. https://doi.org/10.1530/joe-13-0327.CrossRefPubMedPubMedCentral

129.

Leclerc GM, Leclerc GJ, Fu G, Barredo JC. AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal. 2010;5:15. https://doi.org/10.1186/1750-2187-5-15.CrossRefPubMedPubMedCentral

130.

Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, et al. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct Target Ther. 2019;4:20. https://doi.org/10.1038/s41392-019-0050-0.CrossRefPubMedPubMedCentral

131.

Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia. 2007;21:886–96. https://doi.org/10.1038/sj.leu.2404643.CrossRefPubMed

132.

Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179–85. https://doi.org/10.1002/cncr.20071.CrossRefPubMed

133.

Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, et al. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012;11:2314–26. https://doi.org/10.4161/cc.20770.CrossRefPubMedPubMedCentral

134.

Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y, et al. Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med. 2006;209:217–28. https://doi.org/10.1620/tjem.209.217.CrossRefPubMed

135.

Dawczynski K, Kauf E, Schlenvoigt D, Gruhn B, Fuchs D, Zintl F. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant. 2006;37:589–94. https://doi.org/10.1038/sj.bmt.1705281.CrossRefPubMed

136.

Karmali R, Borgia JA, Larson ML, Shammo JM, Basu S, Venugopal P. Impact of circulating members of the insulin-like growth factor receptor (IGF-1R) axis on outcomes in acute myeloid leukemia. J Clin Oncol. 2014;32:7069. https://doi.org/10.1200/jco.2014.32.15_suppl.7069.CrossRef

137.

Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, et al. Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell. 2018;34:659–73.e6. https://doi.org/10.1016/j.ccell.2018.08.016.CrossRefPubMedPubMedCentral

138.

Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: A review of current evidence. Curr Obes Rep. 2023; https://doi.org/10.1007/s13679-023-00518-z.

139.

Lempesis IG, Apple SJ, Duarte G, Palaiodimos L, Kalaitzopoulos DR, Dalamaga M, et al. Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome. Diabetes Metab Res Rev. 2023:e3682. https://doi.org/10.1002/dmrr.3682.

140.

Lempesis IG, Varrias D, Sagris M, Attaran RR, Altin ES, Bakoyiannis C, et al. Obesity and peripheral artery disease: Current evidence and controversies. Curr Obes Rep. 2023:1–16. https://doi.org/10.1007/s13679-023-00510-7.

141.

Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 2011;22:291–9. https://doi.org/10.1007/s10552-010-9697-0.CrossRefPubMed

142.

Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK. Plasma lipid alterations in leukemia and lymphoma. Am J Med. 1982;72:775–82. https://doi.org/10.1016/0002-9343(82)90543-5.CrossRefPubMed

143.

Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91:1519–31. https://doi.org/10.1007/s00277-012-1489-z.CrossRefPubMed

144.

Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, et al. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol. 2014;167:233–7. https://doi.org/10.1111/bjh.13035.CrossRefPubMedPubMedCentral

145.

Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: A phase 1 study. Blood. 2007;109:2999–3006. https://doi.org/10.1182/blood-2006-08-044446.CrossRefPubMedPubMedCentral

146.

Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004;28(Suppl 4):S12–21. https://doi.org/10.1038/sj.ijo.0802853.CrossRefPubMed

147.

Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18:139–43. https://doi.org/10.1097/MED.0b013e3283444b09.CrossRefPubMedPubMedCentral

148.

Hierons SJ, Abbas K, Sobczak AIS, Cerone M, Smith TK, Ajjan RA, et al. Changes in plasma free fatty acids in obese patients before and after bariatric surgery highlight alterations in lipid metabolism. Sci Rep. 2022;12:15337. https://doi.org/10.1038/s41598-022-19657-9.CrossRefPubMedPubMedCentralADS

149.

Fugmann M, Uhl O, Hellmuth C, Hetterich H, Kammer NN, Ferrari U, et al. Differences in the serum nonesterified Fatty Acid profile of young women associated with a recent history of gestational diabetes and overweight/obesity. PLoS One. 2015;10:e0128001. https://doi.org/10.1371/journal.pone.0128001.CrossRefPubMedPubMedCentral

150.

Milligan G, Shimpukade B, Ulven T, Hudson BD. Complex pharmacology of free fatty acid receptors. Chem Rev. 2017;117:67–110. https://doi.org/10.1021/acs.chemrev.6b00056.CrossRefPubMed

151.

Khalid A, Siddiqui AJ, Huang JH, Shamsi T, Musharraf SG. Alteration of serum free fatty acids are indicators for progression of pre-leukaemia diseases to leukaemia. Sci Rep. 2018;8:14883. https://doi.org/10.1038/s41598-018-33224-1.CrossRefPubMedPubMedCentralADS

152.

Tucci J, Chen T, Margulis K, Orgel E, Paszkiewicz RL, Cohen MD, et al. Adipocytes provide fatty acids to acute lymphoblastic leukemia cells. Front Oncol. 2021;11:665763. https://doi.org/10.3389/fonc.2021.665763.CrossRefPubMedPubMedCentral

153.

Culp-Hill R, Stevens BM, Jones CL, Pei S, Dzieciatkowska M, Minhajuddin M, et al. Therapy-resistant acute myeloid leukemia stem cells are resensitized to venetoclax + azacitidine by targeting fatty acid desaturases 1 and 2. Metabolites. 2023:13. https://doi.org/10.3390/metabo13040467.

154.

Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61. https://doi.org/10.1016/j.cell.2009.11.027.CrossRefPubMedPubMedCentral

155.

Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91:6379–83. https://doi.org/10.1073/pnas.91.14.6379.CrossRefPubMedPubMedCentralADS

156.

Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2007;16:1474–8. https://doi.org/10.1158/1055-9965.Epi-07-0143.CrossRefPubMed

157.

Stevenson CE, Takabe K, Nagahashi M, Milstien S, Spiegel S. Targeting sphingosine-1-phosphate in hematologic malignancies. Anticancer Agents Med Chem. 2011;11:794–8. https://doi.org/10.2174/187152011797655122.CrossRefPubMedPubMedCentral

158.

Sun J, Lou Y, Zhu J, Shen H, Zhou D, Zhu L, et al. Hypertriglyceridemia in newly diagnosed acute promyelocytic leukemia. Front Oncol. 2020;10:577796. https://doi.org/10.3389/fonc.2020.577796.CrossRefPubMedPubMedCentral

159.

Usman H, Rashid R, Ameer F, Iqbal A, Zaid M, Hasnain S, et al. Revisiting the dyslipidemia associated with acute leukemia. Clin Chim Acta. 2015;444:43–9. https://doi.org/10.1016/j.cca.2015.01.038.CrossRefPubMed

160.

Scribano D, Baroni S, Pagano L, Zuppi C, Leone G, Giardina B. Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica. 1996;81:343–5.PubMed

161.

Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer. 1998;83:379–84.CrossRefPubMed

162.

Mulas MF, Abete C, Pulisci D, Pani A, Massidda B, Dessì S, et al. Cholesterol esters as growth regulators of lymphocytic leukaemia cells. Cell Prolif. 2011;44:360–71. https://doi.org/10.1111/j.1365-2184.2011.00758.x.CrossRefPubMedPubMedCentral

163.

Bai S, Wang H, Shao R, Fu B, Lu S, Wang J, et al. Lipid profile as a novel prognostic predictor for patients with acute myeloid leukemia. Front Oncol. 2023;13:950732. https://doi.org/10.3389/fonc.2023.950732.CrossRefPubMedPubMedCentral

164.

Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771–82. https://doi.org/10.5551/jat.RV17023.CrossRefPubMedPubMedCentral

165.

Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, et al. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 2004;176:49–56. https://doi.org/10.1016/j.atherosclerosis.2004.04.022.CrossRefPubMed

166.

Wu S, Li S, Jin P, Zhang Y, Chen L, Jin W, et al. Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers. Haematologica. 2022;107:2589–600. https://doi.org/10.3324/haematol.2021.280147.CrossRefPubMedPubMedCentral

167.

Argyrakopoulou G, Dalamaga M, Spyrou N, Kokkinos A. Gender differences in obesity-related cancers. Curr Obes Rep. 2021;10:100–15. https://doi.org/10.1007/s13679-021-00426-0.CrossRefPubMed

168.

Papavasileiou G, Tsilingiris D, Spyrou N, Vallianou NG, Karampela I, Magkos F, et al. Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges. Semin Cancer Biol. 2023;91:70–98. https://doi.org/10.1016/j.semcancer.2023.03.002.CrossRefPubMed

169.

Trakakis E, Papadavid E, Dalamaga M, Koumaki D, Stavrianeas N, Rigopoulos D, et al. Prevalence of non classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with acne: A hospital-based cross-sectional study. J Eur Acad Dermatol Venereol. 2013;27:1448–51. https://doi.org/10.1111/j.1468-3083.2012.04613.x.CrossRefPubMed

170.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–76. https://doi.org/10.1182/blood-2005-06-2508.CrossRefPubMedPubMedCentral

171.

Forsythe A, Breland T, Majumdar S, Elkin TD, Johnson D, Megason G. Gender differences in incidence rates of childhood B-precursor acute lymphocytic leukemia in Mississippi. J Pediatr Oncol Nurs. 2010;27:164–7. https://doi.org/10.1177/1043454209357919.CrossRefPubMed

172.

Roma A, Spagnuolo PA. Estrogen receptors alpha and beta in acute myeloid leukemia. Cancers (Basel). 2020:12. https://doi.org/10.3390/cancers12040907.

173.

Hillisch A, Peters O, Kosemund D, Müller G, Walter A, Schneider B, et al. Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol. 2004;18:1599–609. https://doi.org/10.1210/me.2004-0050.CrossRefPubMed

174.

Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010;5:590–600. https://doi.org/10.4161/epi.5.7.12558.CrossRefPubMedPubMedCentral

175.

Parl FF, Crooke PS, Plummer WD Jr, Dupont WD. Genomic-epidemiologic evidence that estrogens promote breast cancer development. Cancer Epidemiol Biomarkers Prev. 2018;27:899–907. https://doi.org/10.1158/1055-9965.Epi-17-1174.CrossRefPubMedPubMedCentral

176.

Klein HU, Ruckert C, Kohlmann A, Bullinger L, Thiede C, Haferlach T, et al. Quantitative comparison of microarray experiments with published leukemia related gene expression signatures. BMC Bioinform. 2009;10:422. https://doi.org/10.1186/1471-2105-10-422.CrossRef

177.

Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van Waalwijk B, van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617–28. https://doi.org/10.1056/NEJMoa040465.CrossRefPubMed

178.

Rota S-G, Roma A, Dude I, Ma C, Stevens R, MacEachern J, et al. Estrogen receptor β is a novel target in acute myeloid leukemia. Mol Cancer Ther. 2017;16:2618–26. https://doi.org/10.1158/1535-7163.Mct-17-0292.CrossRefPubMed

179.

Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126:1549–64. https://doi.org/10.1161/CIRCRESAHA.119.315896.CrossRefPubMedPubMedCentral

180.

Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996. https://doi.org/10.3389/fimmu.2022.1000996.CrossRefPubMedPubMedCentral

181.

Pérez-Figueroa E, Sánchez-Cuaxospa M, Martínez-Soto KA, Sánchez-Zauco N, Medina-Sansón A, Jiménez-Hernández E, et al. Strong inflammatory response and Th1-polarization profile in children with acute lymphoblastic leukemia without apparent infection. Oncol Rep. 2016;35:2699–706. https://doi.org/10.3892/or.2016.4657.CrossRefPubMed

182.

Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007;26:6738–49. https://doi.org/10.1038/sj.onc.1210758.CrossRefPubMedPubMedCentral

183.

Pasupuleti SK, Ramdas B, Burns SS, Palam LR, Kanumuri R, Kumar R, et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Invest. 2023:133. https://doi.org/10.1172/jci163968.

184.

Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98–105. https://doi.org/10.1016/j.yjmcc.2021.07.004.CrossRefPubMedPubMedCentral

185.

Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132:1553–60. https://doi.org/10.1182/blood-2018-03-784116.CrossRefPubMedPubMedCentral

186.

Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204–18. https://doi.org/10.1016/j.celrep.2017.03.018.CrossRefPubMedPubMedCentral

187.

Paracatu LC, Schuettpelz LG. Contribution of aberrant toll like receptor signaling to the pathogenesis of myelodysplastic syndromes. Front Immunol. 2020;11:1236.CrossRefPubMedPubMedCentral

188.

Stubbins RJ, Platzbecker U, Karsan A. Inflammation and myeloid malignancy: Quenching the flame. Blood, J Am Soc Hematol. 2022;140:1067–74.

189.

Hormaechea-Agulla D, Matatall KA, Le DT, Kain B, Long X, Kus P, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell Stem Cell. 2021;28:1428–42.e6. https://doi.org/10.1016/j.stem.2021.03.002.CrossRefPubMedPubMedCentral

190.

Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27–42.PubMed

191.

Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13:423–44. https://doi.org/10.1089/met.2015.0095.CrossRefPubMedPubMedCentral

192.

Peluso M, Russo V, Mello T, Galli A. Oxidative stress and DNA damage in chronic disease and environmental studies. Int J Mol Sci. 2020:21. https://doi.org/10.3390/ijms21186936.

193.

Udensi UK, Tchounwou PB. Dual effect of oxidative stress on leukemia cancer induction and treatment. J Exp Clin Cancer Res. 2014;33:106. https://doi.org/10.1186/s13046-014-0106-5.CrossRefPubMedPubMedCentral

194.

Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Arch Med Sci. 2013;9:191–200. https://doi.org/10.5114/aoms.2013.33181.CrossRefPubMedPubMedCentral

195.

Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014;220:T47–59. https://doi.org/10.1530/joe-13-0339.CrossRefPubMedPubMedCentral

196.

Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Martín-Rodríguez A, Martínez-Guardado I, Navarro-Jiménez E, et al. The role of adipokines in health and disease. Biomedicines. 2023:11. https://doi.org/10.3390/biomedicines11051290.

197.

Krenn PW, Montanez E, Costell M, Fässler R. Integrins, anchors and signal transducers of hematopoietic stem cells during development and in adulthood. Curr Top Dev Biol. 2022;149:203–61. https://doi.org/10.1016/bs.ctdb.2022.02.009.CrossRefPubMed

198.

Hemmati S, Haque T, Gritsman K. Inflammatory signaling pathways in preleukemic and leukemic stem cells. Front Oncol. 2017;7:265. https://doi.org/10.3389/fonc.2017.00265.CrossRefPubMedPubMedCentral

199.

Camacho V, McClearn V, Patel S, Welner RS. Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. Int J Hematol. 2017;105:566–77. https://doi.org/10.1007/s12185-017-2184-6.CrossRefPubMed

200.

Pietras EM. Inflammation: A key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130:1693–8. https://doi.org/10.1182/blood-2017-06-780882.CrossRefPubMedPubMedCentral

201.

Ahmed HA, Maklad AM, Khaled SA, Elyamany A. Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: Expression and significance as biological markers. J Blood Med. 2019;10:341–9. https://doi.org/10.2147/jbm.S221301.CrossRefPubMedPubMedCentral

202.

Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: Survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013;61:885–91. https://doi.org/10.1016/j.cyto.2012.12.023.CrossRefPubMed

203.

Tao M, Li B, Nayini J, Andrews CB, Huang RW, Devemy E, et al. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine. 2000;12:699–707. https://doi.org/10.1006/cyto.2000.0666.CrossRefPubMed

204.

Elbaz O, Shaltout A. Implication of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL-3) in children with acute myeloid leukaemia (AML); malignancy. Hematology. 2001;5:383–8.CrossRefPubMed

205.

Beauchemin V, Villeneuve L, Rodriguez-Cimadevilla JC, Rajotte D, Kenney JS, Clark SC, et al. Interleukin-6 production by the blast cells of acute myeloblastic leukemia: Regulation by endogenous interleukin-1 and biological implications. J Cell Physiol. 1991;148:353–61. https://doi.org/10.1002/jcp.1041480305.CrossRefPubMed

206.

Villatoro A, Cuminetti V, Bernal A, Torroja C, Cossío I, Benguría A, et al. Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. Nat Commun. 2023;14:12. https://doi.org/10.1038/s41467-022-35700-9.CrossRefPubMedPubMedCentralADS

207.

Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2015;112:10786–91. https://doi.org/10.1073/pnas.1422749112.CrossRefPubMedPubMedCentralADS

208.

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: A promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022:10. https://doi.org/10.1136/jitc-2021-004222.

209.

Hasegawa T, Harada M, Kimura S, Take A, Yoshida I, Horimi H, et al. Four years' experience with the Omniscience prosthetic valve. Kyobu Geka. 1986;39:292–5.PubMed

210.

Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7:57–62. https://doi.org/10.1080/21623945.2017.1402151.CrossRefPubMed

211.

Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D. Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer. 2006;94:156–60. https://doi.org/10.1038/sj.bjc.6602896.CrossRefPubMedPubMedCentral

212.

Aref S, Ibrahim L, Azmy E, Al AR. Impact of serum adiponectin and leptin levels in acute leukemia. Hematology. 2013;18:198–203. https://doi.org/10.1179/1607845412y.0000000059.CrossRefPubMed

213.

El-Baz HA, Mosa TE, Elabd EM, Ramadan A, Elharoun AS, Elmorsy EA, et al. Serum adiponectin and resistin levels in de novo and relapsed acute lymphoblastic leukemia children patients. Iran J Public Health. 2013;42:504–10.PubMedPubMedCentral

214.

Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95:3763–7. https://doi.org/10.1210/jc.2010-0086.CrossRefPubMed

215.

Avcu F, Ural AU, Yilmaz MI, Bingol N, Nevruz O, Caglar K. Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases. Int J Hematol. 2006;83:254–8. https://doi.org/10.1532/ijh97.Na0411.CrossRefPubMed

216.

Bruserud Ø, Huang TS, Glenjen N, Gjertsen BT, Foss B. Leptin in human acute myelogenous leukemia: Studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica. 2002;87:584–95.PubMed

217.

Skoczen S, Tomasik PJ, Gozdzik J, Fijorek K, Krasowska-Kwiecien A, Wiecha O, et al. Visfatin concentrations in children with leukemia before and after stem cell transplantation. Exp Hematol. 2014;42:252–60. https://doi.org/10.1016/j.exphem.2013.12.006.CrossRefPubMed

218.

Hui Z, Liu Z, He A, Chen Y, Zhang P, Lei B, et al. Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17. Eur J Pharmacol. 2019;853:103–10. https://doi.org/10.1016/j.ejphar.2019.03.016.CrossRefPubMed

219.

Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun. 2003;310:927–35. https://doi.org/10.1016/j.bbrc.2003.09.093.CrossRefPubMed

220.

•• Meacham CE, Jeffery EC, Burgess RJ, Sivakumar CD, Arora MA, Stanley AM, et al. Adiponectin receptors sustain haematopoietic stem cells throughout adulthood by protecting them from inflammation. Nat Cell Biol. 2022;24:697–707. https://doi.org/10.1038/s41556-022-00909-9. In this original research study, it was found that adiponectin receptors sustain hematopoietic stem cells throughout adulthood by protecting them from inflammation.CrossRefPubMedPubMedCentral

221.

Demerdash Y, Kain B, Essers MAG, King KY. Yin and Yang: The dual effects of interferons on hematopoiesis. Exp Hematol. 2021;96:1–12. https://doi.org/10.1016/j.exphem.2021.02.002.CrossRefPubMedPubMedCentral

222.

Mouzaki A, Panagoulias I, Dervilli Z, Zolota V, Spadidea P, Rodi M, et al. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine. 2009;48:203–11. https://doi.org/10.1016/j.cyto.2009.07.006.CrossRefPubMed

223.

Kim JY, Park HK, Yoon JS, Kim SJ, Kim ES, Song SH, et al. Molecular mechanisms of cellular proliferation in acute myelogenous leukemia by leptin. Oncol Rep. 2010;23:1369–74. https://doi.org/10.3892/or_00000773.CrossRefPubMed

224.

Foss B, Mentzoni L, Bruserud O. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res. 2001;10:81–93. https://doi.org/10.1089/152581601750098291.CrossRefPubMed

225.

Gorska E, Popko K, Wasik M. Leptin receptor in childhood acute leukemias. Adv Exp Med Biol. 2013;756:155–61. https://doi.org/10.1007/978-94-007-4549-0_20.CrossRefPubMed

226.

Wex H, Ponelis E, Wex T, Dressendörfer R, Mittler U, Vorwerk P. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol. 2002;76:446–52. https://doi.org/10.1007/bf02982810.CrossRefPubMed

227.

Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, et al. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2017;23:79–90. https://doi.org/10.1038/nm.4252.CrossRefPubMed

228.

Schwarzbich M-A, Dai H, Kordelas L, Beelen DW, Radujkovic A, Müller-Tidow C, et al. Pre-transplant serum leptin levels and relapse of acute myeloid leukemia after allogeneic transplantation. Int J Mol Sci. 2022;23:2337.CrossRefPubMedPubMedCentral

229.

Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab. 2014;20:368–75. https://doi.org/10.1016/j.cmet.2014.06.003.CrossRefPubMedPubMedCentral

230.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, et al. Metformin affects cortical bone mass and marrow adiposity in diet-induced obesity in male mice. Endocrinology. 2017;158:3369–85. https://doi.org/10.1210/en.2017-00299.CrossRefPubMedPubMedCentral

231.

Tencerova M, Figeac F, Ditzel N, Taipaleenmäki H, Nielsen TK, Kassem M. High-fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice. J Bone Miner Res. 2018;33:1154–65. https://doi.org/10.1002/jbmr.3408.CrossRefPubMed

232.

Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009;460:259–63. https://doi.org/10.1038/nature08099.CrossRefPubMedPubMedCentralADS

233.

Zhu RJ, Wu MQ, Li ZJ, Zhang Y, Liu KY. Hematopoietic recovery following chemotherapy is improved by BADGE-induced inhibition of adipogenesis. Int J Hematol. 2013;97:58–72. https://doi.org/10.1007/s12185-012-1233-4.CrossRefPubMed

234.

Zioni N, Bercovich AA, Chapal-Ilani N, Bacharach T, Rappoport N, Solomon A, et al. Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis. Nat Commun. 2023;14:2070. https://doi.org/10.1038/s41467-023-36906-1.CrossRefPubMedPubMedCentralADS

235.

Boyd AL, Reid JC, Salci KR, Aslostovar L, Benoit YD, Shapovalova Z, et al. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nat Cell Biol. 2017;19:1336–47. https://doi.org/10.1038/ncb3625.CrossRefPubMed

236.

Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129:1320–32. https://doi.org/10.1182/blood-2016-08-734798.CrossRefPubMed

237.

Cahu X, Calvo J, Poglio S, Prade N, Colsch B, Arcangeli ML, et al. Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. Blood Adv. 2017;1:1760–72. https://doi.org/10.1182/bloodadvances.2017004960.CrossRefPubMedPubMedCentral

238.

Orgel E, Sea JL, Mittelman SD. Mechanisms by which obesity impacts survival from acute lymphoblastic leukemia. J Natl Cancer Inst Monogr. 2019;2019:152–6. https://doi.org/10.1093/jncimonographs/lgz020.CrossRefPubMedPubMedCentral

239.

Vicente López Á, Vázquez García MN, Melen GJ, Entrena Martínez A, Cubillo Moreno I, García-Castro J, et al. Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: Correlations with the course of disease. PLoS One. 2014;9:e84496. https://doi.org/10.1371/journal.pone.0084496.CrossRefPubMedPubMedCentralADS

240.

Liu T, Kishton RJ, Macintyre AN, Gerriets VA, Xiang H, Liu X, et al. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis. 2014;5:e1470. https://doi.org/10.1038/cddis.2014.431.CrossRefPubMedPubMedCentral

241.

van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91:56–63.

242.

Tucci J, Sheng X, Mittelman SD. Acute lymphoblastic leukemia cells stimulate adipocyte lipolysis and utilize adipocyte-derived free-fatty acids for proliferation. Cancer Res. 2014;74:4339.CrossRef

243.

Zhou R, Liang T, Li T, Huang J, Chen C. Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia. Front Oncol. 2023;13:1070069. https://doi.org/10.3389/fonc.2023.1070069.CrossRefPubMedPubMedCentral

244.

Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–95. https://doi.org/10.1091/mbc.e02-02-0105.CrossRefPubMedPubMedCentral

245.

Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: Cancer metabolism. J Clin Oncol. 2016;34:4277–83. https://doi.org/10.1200/jco.2016.67.9712.CrossRefPubMedPubMedCentral

246.

Lee MW, Park YJ, Kim DS, Park HJ, Jung HL, Lee JW, et al. Human adipose tissue stem cells promote the growth of acute lymphoblastic leukemia cells in NOD/SCID mice. Stem Cell Rev Rep. 2018;14:451–60. https://doi.org/10.1007/s12015-018-9806-0.CrossRefPubMed

247.

Lee MW, Ryu S, Kim DS, Lee JW, Sung KW, Koo HH, et al. Mesenchymal stem cells in suppression or progression of hematologic malignancy: Current status and challenges. Leukemia. 2019;33:597–611. https://doi.org/10.1038/s41375-018-0373-9.CrossRefPubMedPubMedCentral

248.

Wang YC, Chen RF, Brandacher G, Lee WPA, Kuo YR. The suppression effect of dendritic cells maturation by adipose-derived stem cells through TGF-β1 related pathway. Exp Cell Res. 2018;370:708–17. https://doi.org/10.1016/j.yexcr.2018.07.037.CrossRefPubMed

249.

Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesity-related insulin resistance. Scand J Immunol. 2019;89:e12747. https://doi.org/10.1111/sji.12747.CrossRefPubMed

250.

Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;7:66–75. https://doi.org/10.3945/an.115.010207.CrossRefPubMedPubMedCentral

251.

Sbierski-Kind J, Goldeck D, Buchmann N, Spranger J, Volk HD, Steinhagen-Thiessen E, et al. T cell phenotypes associated with insulin resistance: Results from the Berlin Aging Study II. Immun Ageing. 2020;17:40. https://doi.org/10.1186/s12979-020-00211-y.CrossRefPubMedPubMedCentral

252.

Barrett AJ. Acute myeloid leukaemia and the immune system: Implications for immunotherapy. Br J Haematol. 2020;188:147–58. https://doi.org/10.1111/bjh.16310.CrossRefPubMed

253.

Pastorczak A, Domka K, Fidyt K, Poprzeczko M, Firczuk M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers (Basel). 2021:13. https://doi.org/10.3390/cancers13071536.

254.

Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81. https://doi.org/10.1182/blood-2015-03-567388.CrossRefPubMed

255.

Koldej RM, Prabahran A, Tan CW, Ng AP, Davis MJ, Ritchie DS. Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers. Sci Rep. 2021;11:19056. https://doi.org/10.1038/s41598-021-98536-1.CrossRefPubMedPubMedCentralADS

256.

Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022:132. https://doi.org/10.1172/jci159579.

257.

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30:492–506. https://doi.org/10.1038/s41422-020-0332-7.CrossRefPubMedPubMedCentral

258.

Shi SQ, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol. 2013;23:372–81. https://doi.org/10.1016/j.cub.2013.01.048.CrossRefPubMedPubMedCentral

259.

Škrlec I, Talapko J, Džijan S, Cesar V, Lazić N, Lepeduš H. The association between circadian clock gene polymorphisms and metabolic syndrome: A systematic review and meta-analysis. Biology (Basel). 2021:11. https://doi.org/10.3390/biology11010020.

260.

Sardon Puig L, Pillon NJ, Näslund E, Krook A, Zierath JR. Influence of obesity, weight loss, and free fatty acids on skeletal muscle clock gene expression. Am J Physiol Endocrinol Metab. 2020;318:E1–e10. https://doi.org/10.1152/ajpendo.00289.2019.CrossRefPubMed

261.

Hanoun M, Eisele L, Suzuki M, Greally JM, Hüttmann A, Aydin S, et al. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One. 2012;7:e34347. https://doi.org/10.1371/journal.pone.0034347.CrossRefPubMedPubMedCentralADS

262.

Sun CM, Huang SF, Zeng JM, Liu DB, Xiao Q, Tian WJ, et al. Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction. Pathol Oncol Res. 2010;16:403–11. https://doi.org/10.1007/s12253-009-9227-0.CrossRefPubMed

263.

Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, et al. Core circadian clock genes regulate leukemia stem cells in AML. Cell. 2016;165:303–16. https://doi.org/10.1016/j.cell.2016.03.015.CrossRefPubMedPubMedCentral

264.

Dessypris N, Karalexi MA, Ntouvelis E, Diamantaras AA, Papadakis V, Baka M, et al. Association of maternal and index child's diet with subsequent leukemia risk: A systematic review and meta analysis. Cancer Epidemiol. 2017;47:64–75. https://doi.org/10.1016/j.canep.2017.01.003.CrossRefPubMed

265.

Diamantaras AA, Dessypris N, Sergentanis TN, Ntouvelis E, Athanasiadou-Piperopoulou F, Baka M, et al. Nutrition in early life and risk of childhood leukemia: A case-control study in Greece. Cancer Causes Control. 2013;24:117–24. https://doi.org/10.1007/s10552-012-0097-5.CrossRefPubMed

266.

Solans M, Castelló A, Benavente Y, Marcos-Gragera R, Amiano P, Gracia-Lavedan E, et al. Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. Haematologica. 2018;103:1881–8. https://doi.org/10.3324/haematol.2018.192526.CrossRefPubMedPubMedCentral

267.

Gery S, Koeffler HP. Per2 is a C/EBP target gene implicated in myeloid leukemia. Integr Cancer Ther. 2009;8:317–20. https://doi.org/10.1177/1534735409352084.CrossRefPubMed

268.

Deota S, Lin T, Chaix A, Williams A, Le H, Calligaro H, et al. Diurnal transcriptome landscape of a multi-tissue response to time-restricted feeding in mammals. Cell Metab. 2023;35:150–65.e4. https://doi.org/10.1016/j.cmet.2022.12.006.CrossRefPubMedPubMedCentral

269.

Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA. Intern Med. 2016;176:816–25. https://doi.org/10.1001/jamainternmed.2016.1548.CrossRef

270.

Rees-Punia E, Patel AV, Fallon EA, Gapstur SM, Teras LR. Physical activity, sitting time, and risk of myelodysplastic syndromes, acute myeloid leukemia, and other myeloid malignancies. Cancer Epidemiol Biomarkers Prev. 2019;28:1489–94. https://doi.org/10.1158/1055-9965.Epi-19-0232.CrossRefPubMed

271.

Orgel E, Framson C, Buxton R, Kim J, Li G, Tucci J, et al. Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: The IDEAL trial. Blood Adv. 2021;5:1853–61. https://doi.org/10.1182/bloodadvances.2020004018.CrossRefPubMedPubMedCentral

272.

Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–62. https://doi.org/10.1016/s1470-2045(09)70159-7.CrossRefPubMed

273.

Tao W, Santoni G, von Euler-Chelpin M, Ljung R, Lynge E, Pukkala E, et al. Cancer risk after bariatric surgery in a cohort study from the five nordic countries. Obes Surg. 2020;30:3761–7. https://doi.org/10.1007/s11695-020-04751-6.CrossRefPubMedPubMedCentral

274.

Kumar P, Hamza N, Madhok B, De Alwis N, Sharma M, Miras AD, et al. Copper deficiency after gastric bypass for morbid obesity: A systematic review. Obes Surg. 2016;26:1335–42. https://doi.org/10.1007/s11695-016-2162-8.CrossRefPubMed

275.

Argyrakopoulou G, Konstantinidou SK, Dalamaga M, Kokkinos A. Nutritional deficiencies before and after bariatric surgery: Prevention and treatment. Curr Nutr Rep. 2022;11:95–101. https://doi.org/10.1007/s13668-022-00400-9.CrossRefPubMed

276.

Luo T, Zurko J, Astle J, Shah NN. Mimicking myelodysplastic syndrome: Importance of differential diagnosis. Case Rep Hematol. 2021;2021:9661765. https://doi.org/10.1155/2021/9661765.CrossRefPubMedPubMedCentral

277.

D'Angelo G. Copper deficiency mimicking myelodysplastic syndrome. Blood Res. 2016;51:217–9. https://doi.org/10.5045/br.2016.51.4.217.CrossRefPubMedPubMedCentral

278.

Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019;92:61–70. https://doi.org/10.1016/j.metabol.2018.12.006.CrossRefPubMed

279.

Dalamaga M, Christodoulatos GS. Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Horm Mol Biol Clin Investig. 2015;23:5–20. https://doi.org/10.1515/hmbci-2015-0016.CrossRefPubMed

280.

Dalamaga M, Polyzos SA, Karmaniolas K, Chamberland J, Lekka A, Triantafilli M, et al. Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: A hospital-based case-control study. Leuk Lymphoma. 2016;57:577–84. https://doi.org/10.3109/10428194.2015.1075523.CrossRefPubMed

281.

Dalamaga M, Karmaniolas K, Nikolaidou A, Chamberland J, Hsi A, Dionyssiou-Asteriou A, et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer. 2008;44:1744–53. https://doi.org/10.1016/j.ejca.2008.04.015.CrossRefPubMed

282.

Dalamaga M, Karmaniolas K, Matekovits A, Migdalis I, Papadavid E. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients. J Eur Acad Dermatol Venereol. 2008;22:543–8. https://doi.org/10.1111/j.1468-3083.2007.02520.x.CrossRefPubMed

283.

Ambrosi TH, Scialdone A, Graja A, Gohlke S, Jank AM, Bocian C, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell. 2017;20:771–84.e6. https://doi.org/10.1016/j.stem.2017.02.009.CrossRefPubMedPubMedCentral

284.

Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, et al. High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia. Sci Rep. 2022;12:8885. https://doi.org/10.1038/s41598-022-12813-1.CrossRefPubMedPubMedCentralADS

285.

Tang HN, Pan BH, Wang L, Zhu HY, Fan L, Xu W, et al. C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases. Transl Oncol. 2021;14:101035. https://doi.org/10.1016/j.tranon.2021.101035.CrossRefPubMedPubMedCentral

286.

Stevens AM, Miller JM, Munoz JO, Gaikwad AS, Redell MS. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv. 2017;1:1387–97. https://doi.org/10.1182/bloodadvances.2017007856.CrossRefPubMedPubMedCentral

287.

Sharma K, Singh U, Rai M, Shukla J, Gupta V, Narayan G, et al. Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study. J Cancer Res Ther. 2020;16:30–3. https://doi.org/10.4103/jcrt.JCRT_137_17.CrossRefPubMed

288.

Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et al. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124:528–42. https://doi.org/10.1172/jci68101.CrossRefPubMedPubMedCentral

289.

Verma S, Singh A, Yadav G, Kushwaha R, Ali W, Verma SP, et al. Serum tumor necrosis factor-alpha levels in acute leukemia and its prognostic significance. Cureus. 2022;14:e24835. https://doi.org/10.7759/cureus.24835.CrossRefPubMedPubMedCentral

290.

Picó C, Palou M, Pomar CA, Rodríguez AM, Palou A. Leptin as a key regulator of the adipose organ. Rev Endocr Metab Disord. 2022;23:13–30. https://doi.org/10.1007/s11154-021-09687-5.CrossRefPubMed

291.

Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptotic activities. Blood. 1999;93:1668–76.CrossRefPubMed

292.

Hamed NA, Sharaki OA, Zeidan MM. Leptin in acute leukaemias: Relationship to interleukin-6 and vascular endothelial growth factor. Egypt J Immunol. 2003;10:57–66.PubMed

293.

Yilmaz M, Kis C, Ceylan NO, Okan V, Pehlivan M, Kuçukosmanoglu E, et al. Serum leptin level in acute myeloid leukemia patients. Hematology. 2008;13:21–3. https://doi.org/10.1179/102453308x315771.CrossRefPubMed

294.

Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: Correlation with clinical characteristics. Exp Oncol. 2006;28:241–4.PubMed

295.

Bansal P, Ghalaut VS, Sharma TK, Ghalaut PS, Dokwal S, Ghalaut R, et al. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: A conflicting scenario. Clin Lab. 2014;60:1845–52. https://doi.org/10.7754/clin.lab.2014.140126.CrossRefPubMed

296.

Forny-Germano L, De Felice FG, Vieira M. The role of leptin and adiponectin in obesity-associated cognitive decline and alzheimer's disease. Front Neurosci. 2018;12:1027. https://doi.org/10.3389/fnins.2018.01027.CrossRefPubMed

297.

Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014:658913. https://doi.org/10.1155/2014/658913.CrossRefPubMedPubMedCentral

298.

Dalamaga M, Nikolaidou A, Karmaniolas K, Hsi A, Chamberland J, Dionyssiou-Asteriou A, et al. Circulating adiponectin and leptin in relation to myelodysplastic syndrome: A case-control study. Oncology. 2007;73:26–32. https://doi.org/10.1159/000120995.CrossRefPubMed

299.

Karampela I, Christodoulatos GS, Kandri E, Antonakos G, Vogiatzakis E, Dimopoulos G, et al. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study. Cytokine. 2019;119:62–70. https://doi.org/10.1016/j.cyto.2019.03.002.CrossRefPubMed

300.

Huang X, Yang Z. Resistin's, obesity and insulin resistance: The continuing disconnect between rodents and humans. J Endocrinol Invest. 2016;39:607–15. https://doi.org/10.1007/s40618-015-0408-2.CrossRefPubMed

301.

Marouga A, Dalamaga M, Kastania AN, Antonakos G, Thrasyvoulides A, Kontelia G, et al. Correlates of serum resistin in elderly, non-diabetic patients with chronic kidney disease. Clin Lab. 2013;59:1121–8. https://doi.org/10.7754/clin.lab.2012.121112.CrossRefPubMed

302.

Abdalla MMI. Role of visfatin in obesity-induced insulin resistance. World J Clin Cases. 2022;10:10840–51. https://doi.org/10.12998/wjcc.v10.i30.10840.CrossRefPubMedPubMedCentral

303.

Budakoti M, Panwar AS, Molpa D, Singh RK, Büsselberg D, Mishra AP, et al. Micro-RNA: The darkhorse of cancer. Cell Signal. 2021;83:109995. https://doi.org/10.1016/j.cellsig.2021.109995.CrossRefPubMed

304.

Gharanei S, Shabir K, Brown JE, Weickert MO, Barber TM, Kyrou I, et al. Regulatory microRNAs in brown, brite and white adipose tissue. Cells. 2020:9. https://doi.org/10.3390/cells9112489.

305.

Peng B, Theng PY, Le MTN. Essential functions of miR-125b in cancer. Cell Prolif. 2021;54:e12913. https://doi.org/10.1111/cpr.12913.CrossRefPubMed

306.

Al Azzouny MA, Behiry EG, Behairy OG, Abd Ellraouf HA, Elfallah AA. Serum microRNA-486-5p expression in obese Egyptian children and its possible association with fatty liver. Diabetes Metab Syndr. 2021;15:102258. https://doi.org/10.1016/j.dsx.2021.102258.CrossRefPubMed

307.

Wang LS, Li L, Li L, Chu S, Shiang KD, Li M, et al. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood. 2015;125:1302–13. https://doi.org/10.1182/blood-2014-06-581926.CrossRefPubMedPubMedCentral

308.

Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia. 2013;56:1971–9. https://doi.org/10.1007/s00125-013-2950-9.CrossRefPubMedPubMedCentral

309.

Chan GCK, Than WH, Kwan BCH, Lai KB, Chan RCK, Teoh JYC, et al. Adipose and plasma microRNAs miR-221 and 222 associate with obesity, insulin resistance, and new onset diabetes after peritoneal dialysis. Nutrients. 2022:14. https://doi.org/10.3390/nu14224889.

310.

Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA, Lodish HF. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle. 2010;9:1037–42. https://doi.org/10.4161/cc.9.6.11011.CrossRefPubMed

311.

Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma. 2019;60:1709–20. https://doi.org/10.1080/10428194.2018.1543875.CrossRefPubMed

312.

Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 2010;9:123. https://doi.org/10.1186/1476-4598-9-123.CrossRefPubMedPubMedCentral

313.

Al-Rawaf HA. Circulating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesity. Clin Nutr. 2019;38:2231–8. https://doi.org/10.1016/j.clnu.2018.09.024.CrossRefPubMed

314.

Zhang Y, Liu Y, Xu X. Upregulation of miR-142-3p improves drug sensitivity of acute myelogenous leukemia through reducing p-glycoprotein and repressing autophagy by targeting HMGB1. Transl Oncol. 2017;10:410–8. https://doi.org/10.1016/j.tranon.2017.03.003.CrossRefPubMedPubMedCentral

315.

Pepe MG, Ginzton NH, Lee PD, Hintz RL, Greenberg PL. Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells. J Cell Physiol. 1987;133:219–27. https://doi.org/10.1002/jcp.1041330204.CrossRefPubMed

316.

Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood. 2008;111:379–82. https://doi.org/10.1182/blood-2007-03-080796.CrossRefPubMed

317.

Rodrigues Alves APN, Fernandes JC, Fenerich BA, Coelho-Silva JL, Scheucher PS, Simões BP, et al. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Lett. 2019;456:59–68. https://doi.org/10.1016/j.canlet.2019.04.030.CrossRefPubMed

318.

Artico LL, Laranjeira ABA, Campos LW, Corrêa JR, Zenatti PP, Carvalheira JBC, et al. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. Blood Adv. 2021;5:3633–46. https://doi.org/10.1182/bloodadvances.2020003627.CrossRefPubMedPubMedCentral

319.

Lakshmikuttyamma A, Pastural E, Takahashi N, Sawada K, Sheridan DP, DeCoteau JF, et al. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene. 2008;27:3831–44. https://doi.org/10.1038/onc.2008.8.CrossRefPubMed

320.

Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020:21. https://doi.org/10.3390/ijms21082907.

321.

Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2014;28:739–48. https://doi.org/10.1038/leu.2013.226.CrossRefPubMed

322.

Adam E, Kim HN, Gang EJ, Schnair C, Lee S, Lee S, et al. The PI3Kδ inhibitor idelalisib inhibits homing in an in vitro and in vivo model of B ALL. Cancers (Basel). 2017:9. https://doi.org/10.3390/cancers9090121.

323.

Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, et al. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27062. https://doi.org/10.1002/pbc.27062.CrossRefPubMed

324.

Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, et al. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: A phase Ib/II study. Oncotarget. 2017;8:52269–80. https://doi.org/10.18632/oncotarget.13699.CrossRefPubMed

325.

Kuwatsuka Y, Minami M, Minami Y, Sugimoto K, Hayakawa F, Miyata Y, et al. The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J. 2011;1:e17. https://doi.org/10.1038/bcj.2011.16.CrossRefPubMedPubMedCentral

326.

Silic-Benussi M, Sharova E, Ciccarese F, Cavallari I, Raimondi V, Urso L, et al. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biol. 2022;51:102268. https://doi.org/10.1016/j.redox.2022.102268.CrossRefPubMedPubMedCentral

327.

Tasian SK, Silverman LB, Whitlock JA, Sposto R, Loftus JP, Schafer ES, et al. Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022;107:2295–303. https://doi.org/10.3324/haematol.2021.279520.CrossRefPubMedPubMedCentral

328.

Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, et al. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: A Children's Oncology Group study (ADVL1114). Br J Haematol. 2017;177:467–74. https://doi.org/10.1111/bjh.14569.CrossRefPubMedPubMedCentral

329.

Scotland S, Micklow E, Wang Z, Boutzen H, Récher C, Danet-Desnoyers G, et al. Metformin for therapeutic intervention in acute myeloid leukemia. Blood. 2010;116:4351. https://doi.org/10.1182/blood.V116.21.4351.4351.CrossRef

330.

Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010;116:4262–73. https://doi.org/10.1182/blood-2010-02-269837.CrossRefPubMed

331.

Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H, et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett. 2013;336:114–26. https://doi.org/10.1016/j.canlet.2013.04.015.CrossRefPubMed

332.

Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood. 2011;118:6399–402. https://doi.org/10.1182/blood-2011-01-332783.CrossRefPubMedPubMedCentral

333.

Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget. 2013;4:2550–66. https://doi.org/10.18632/oncotarget.1508.CrossRefPubMed

334.

Bruno S, Ledda B, Tenca C, Ravera S, Orengo AM, Mazzarello AN, et al. Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. Oncotarget. 2015;6:22624–40. https://doi.org/10.18632/oncotarget.4168.CrossRefPubMedPubMedCentral

335.

Adekola KU, Dalva Aydemir S, Ma S, Zhou Z, Rosen ST, Shanmugam M. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma. 2015;56:450–9. https://doi.org/10.3109/10428194.2014.922180.CrossRefPubMed

336.

Tseng CH. Metformin use and leukemia risk in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020;11:541090. https://doi.org/10.3389/fendo.2020.541090.CrossRefPubMedPubMedCentral

337.

Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, et al. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 1999;261:833–7. https://doi.org/10.1006/bbrc.1999.1049.CrossRefPubMed

338.

Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R, et al. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology. 1999;57(Suppl 2):17–26. https://doi.org/10.1159/000055271.CrossRefPubMed

339.

Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, et al. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004;3:1249–62.CrossRefPubMed

340.

Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q, et al. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol. 2005;16:455–9. https://doi.org/10.1093/annonc/mdi077.CrossRefPubMed

341.

Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T, et al. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol. 2006;116:30–40. https://doi.org/10.1159/000092345.CrossRefPubMed

342.

Saiki M, Hatta Y, Yamazaki T, Itoh T, Enomoto Y, Takeuchi J, et al. Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells. Int J Oncol. 2006;29:437–43.PubMed

343.

Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature. 2015;525:380–3. https://doi.org/10.1038/nature15248.CrossRefPubMedADS

344.

Scatena R, Nocca G, Sole PD, Rumi C, Puggioni P, Remiddi F, et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 1999;6:781–7. https://doi.org/10.1038/sj.cdd.4400551.CrossRefPubMed

345.

Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP, et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood. 2006;107:3683–92. https://doi.org/10.1182/blood-2005-05-2103.CrossRefPubMed

346.

Friedman DR, Magura LA, Warren HA, Harrison JD, Diehl LF, Weinberg JB. Statin use and need for therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:2295–8. https://doi.org/10.3109/10428194.2010.520050.CrossRefPubMed

347.

Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51:1233–40. https://doi.org/10.3109/10428194.2010.486877.CrossRefPubMedPubMedCentral

348.

Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010;89:1115–24. https://doi.org/10.1007/s00277-010-0988-z.CrossRefPubMedPubMedCentral

349.

Yavasoglu I, Sargin G, Kadikoylu G, Karul A, Bolaman Z. The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro. Med Oncol. 2013;30:603. https://doi.org/10.1007/s12032-013-0603-y.CrossRefPubMed

350.

Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, et al. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:1424–6. https://doi.org/10.1182/blood-2013-07-517102.CrossRefPubMedPubMedCentral

351.

Chow S, Buckstein R, Spaner DE. A link between hypercholesterolemia and chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57:797–802. https://doi.org/10.3109/10428194.2015.1088651.CrossRefPubMed

352.

Henslee AB, Steele TA. Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia. Biomark Res. 2018;6:26. https://doi.org/10.1186/s40364-018-0140-0.CrossRefPubMedPubMedCentral

353.

Gimenez N, Tripathi R, Giró A, Rosich L, López-Guerra M, López-Oreja I, et al. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Sci Rep. 2020;10:22153. https://doi.org/10.1038/s41598-020-78315-0.CrossRefPubMedPubMedCentralADS

354.

Righolt CH, Zhang G, Ye X, Banerji V, Johnston JB, Gibson S, et al. Statin use and chronic lymphocytic leukemia incidence: A nested case-control study in Manitoba, Canada. Cancer Epidemiol Biomarkers Prev. 2019;28:1495–501. https://doi.org/10.1158/1055-9965.Epi-19-0107.CrossRefPubMed

355.

Jang HJ, Woo YM, Naka K, Park JH, Han HJ, Kim HJ, et al. Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors. Cancers (Basel). 2021:13. https://doi.org/10.3390/cancers13215543.

356.

Brånvall E, Ekberg S, Eloranta S, Wästerlid T, Birmann BM, Smedby KE. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. Br J Haematol. 2021;195:552–60. https://doi.org/10.1111/bjh.17733.CrossRefPubMed

357.

Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D, et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood. 1998;92:1406–14.CrossRefPubMed

358.

Weiss JR, Baker JA, Baer MR, Menezes RJ, Nowell S, Moysich KB. Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res. 2006;30:164–9. https://doi.org/10.1016/j.leukres.2005.06.023.CrossRefPubMed

359.

Iglesias-Serret D, Piqué M, Barragán M, Cosialls AM, Santidrián AF, González-Gironès DM, et al. Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis. 2010;15:219–29. https://doi.org/10.1007/s10495-009-0424-9.CrossRefPubMed

360.

Ross JA, Blair CK, Cerhan JR, Soler JT, Hirsch BA, Roesler MA, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2011;20:1741–50. https://doi.org/10.1158/1055-9965.Epi-11-0411.CrossRefPubMedPubMedCentral

361.

Liang S, Zhou X, Cai D, Rodrigues-Lima F, Chi J, Wang L. Network pharmacology and experimental validation reveal the effects of chidamide combined with aspirin on acute myeloid leukemia-myelodysplastic syndrome cells through PI3K/AKT pathway. Front Cell Dev Biol. 2021;9:685954. https://doi.org/10.3389/fcell.2021.685954.CrossRefPubMedPubMedCentral

362.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–85. https://doi.org/10.1007/s00125-017-4342-z.CrossRefPubMedPubMedCentral

363.

Chang WH, Lai AG. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types. BMC Cancer. 2020;20:773. https://doi.org/10.1186/s12885-020-07286-2.CrossRefPubMedPubMedCentral

364.

Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006;42:39–64. https://doi.org/10.1358/dot.2006.42.1.963528.CrossRefPubMed

365.

Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008;5:e64. https://doi.org/10.1371/journal.pmed.0050064.CrossRefPubMedPubMedCentral

366.

Tsilingiris D, Nasiri-Ansari N, Spyrou N, Magkos F, Dalamaga M. Management of hematologic malignancies in the era of COVID-19 pandemic: Pathogenetic mechanisms, impact of obesity, perspectives, and challenges. Cancers (Basel). 2022:14. https://doi.org/10.3390/cancers14102494.

367.

Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:e16–20. https://doi.org/10.1111/bjh.16801.CrossRefPubMedPubMedCentral

368.

Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, et al. Treating leukemia in the time of COVID-19. Acta Haematol. 2021;144:132–45. https://doi.org/10.1159/000508199.CrossRefPubMed

369.

Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N, et al. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood. 2022;140:2709–21. https://doi.org/10.1182/blood.2022017814.CrossRefPubMed

370.

Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, et al. COVID-19 in B cell-depleted patients after rituximab: A diagnostic and therapeutic challenge. Front Immunol. 2021;12:763412. https://doi.org/10.3389/fimmu.2021.763412.CrossRefPubMedPubMedCentral

371.

Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: Clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022;11:28. https://doi.org/10.1186/s13756-022-01067-1.CrossRefPubMedPubMedCentral

372.

Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021;39:1297–9. https://doi.org/10.1016/j.ccell.2021.09.001.CrossRefPubMedPubMedCentral

373.

•• Larson EA, Dalamaga M, Magkos F. The role of exercise in obesity-related cancers: Current evidence and biological mechanisms. Semin Cancer Biol. 2023;91:16–26. https://doi.org/10.1016/j.semcancer.2023.02.008. This review summarizes recent evidence on the effect of physical activity on obesity-related cancer prevention and survival.CrossRefPubMed

374.

Verde L, Dalamaga M, Capó X, Annunziata G, Hassapidou M, Docimo A, et al. The antioxidant potential of the Mediterranean diet as a predictor of weight loss after a very low-calorie ketogenic diet (VLCKD) in women with overweight and obesity. Antioxidants (Basel). 2022:12. https://doi.org/10.3390/antiox12010018.

375.

Muscogiuri G, Verde L, Sulu C, Katsiki N, Hassapidou M, Frias-Toral E, et al. Mediterranean diet and obesity-related disorders: What is the evidence? Curr Obes Rep. 2022;11:287–304. https://doi.org/10.1007/s13679-022-00481-1.CrossRefPubMedPubMedCentral

376.

Rokou A, Eleftheriou A, Tsigalou C, Apessos I, Nena E, Dalamaga M, et al. Effect of the implementation of a structured diet management plan on the severity of obstructive sleep apnea: A systematic review. Curr Nutr Rep. 2023;12:26–38. https://doi.org/10.1007/s13668-022-00445-w.CrossRefPubMed

377.

Lempesis IG, Liu J, Dalamaga M. The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity. Metabol Open. 2022;16:100220. https://doi.org/10.1016/j.metop.2022.100220.CrossRefPubMedPubMedCentral

378.

Vallianou NG, Tsilingiris D, Kounatidis D, Lempesis IG, Karampela I, Dalamaga M. Sodium-glucose cotransporter-2 inhibitors in obesity and associated cardiometabolic disorders: Where do we stand? Pol. Arch Intern Med. 2022:132. https://doi.org/10.20452/pamw.16342.

379.

Kounatidis D, Vallianou NG, Tsilingiris D, Christodoulatos GS, Geladari E, Stratigou T, et al. Therapeutic potential of GLP-2 analogs in gastrointestinal disorders: Current knowledge, nutritional aspects, and future perspectives. Curr Nutr Rep. 2022;11:618–42. https://doi.org/10.1007/s13668-022-00433-0.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

The Physiological Effects of Weight-Cycling: A Review of Current Evidence

Is Endoscopic Surveillance Needed After Laparoscopic Sleeve Gastrectomy?

Weight Loss Diets, Fads, and Trends

Prenatal Exposure to Cannabis: Effects on Childhood Obesity and Cardiometabolic Health

Body Composition Changes in Adolescents Who Underwent Bariatric Surgery: A Systematic Review and Meta-analysis

Single Anastomosis Duodenoileostomy with Sleeve: A Comprehensive Review of Anatomy, Surgical Technique, and Outcomes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials